Announcement:
Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma
New Blog Post:
First-in-Human Results for GB-0669: Durable Neutralization from an AI-Designed Antibody
